ugh donor agencies. Dr. Fortunak teaches a four-course sequence in drug development for African Pharmaceutical Companies and National Drug Regulators at the St. Luke Foundation / Kilimanjaro School of Pharmacy in Moshi, Tanzania
; to reduce the incidence of counterfeiting and encourage the availability of quality-assured medicines in sub-Saharan Africa. The WHO ANDI (African Network for Drugs and Diagnostics Innovation) has designated the SLF/KSP as a Center of Excellence in drug manufacturing and training. His research interests lie in Green Chemical Processing, new synthetic methods, and new applications of asymmetric synthesis. Dr. Fortunak received a PhD in organic chemistry from the University of Wisconsin, and a postdoctoral stint at Cambridge University.
Dr. Fortunak commented, "I'm excited to become a member of the TNIB team and look forward to helping TNIB capitalize on its therapies and business plans for African and other emerging nations."
About TNI BioTech, Inc.
TNI BioTech, Inc. is a biotech company with the goal of benefitting patients with chronic and often life-threatening diseases through the activation and rebalancing of the body's immune system, using a patented immunotherapy.
Their products, technologies, and patents are designed to harness the power of the immune system to improve the treatment of cancer, chronic infections such as HIV/AIDS, and autoimmune diseases and, such as Crohn's disease, other types of inflammatory bowel disease, and multiple sclerosis (MS).
TNI BioTech's most advanced clinical programs involve immunotherapy with methionine-enkephalin (MENK) or low dose naltrexone (LDN), which both work by triggering opioid receptors on immune cells, leading to an activation and expansion of various cells of the immune system.
Their proprietary technology, therapies, and patents are planned to treat a wide range of cancers. Their most advanced clinical progPage: 1 2 3 4 Related biology technology :1
. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of PROLOR Biotech, Inc. in Connection with the Sale of the Company to OPKO Health, Inc.2
. Law Office of Brodsky & Smith, LLC Announces Investigation of PROLOR Biotech, Inc.3
. Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech, 2013 Edition4
. Air Products to Feature Medical and Industrial Grade Gas Solutions for Pharma, Biotech, and Life Science Applications at Mid-Atlantic Bio Conference5
. RayBiotech, Inc. Achieves Both GMP- and GLP-Compliance and Announces New Dedicated Services Laboratory6
. RayBiotech, Inc. and the University of Oslo Enter into Antibody Array Services Collaboration7
. RayBiotech, Inc. Announces New Diagnostic Core Facility Partnering Program8
. Marina Biotech, Inc. Joins OTCQX9
. Janssen Biotech, Inc. Announces Collaborative Development and Worldwide License Agreement for Investigational Anti-Cancer Drug, PCI-3276510
. VentiRx Pharmaceuticals Appoints James Kyle Bryan, M.D. as Chief Medical Officer11
. OHK Medical Devices appoints Mr. Omer Inbar as Chief Executive Officer